InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: None

Wednesday, 10/04/2017 7:38:14 AM

Wednesday, October 04, 2017 7:38:14 AM

Post# of 1954
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Treatment with VK0214 led to Significant Reductions in Plasma and Tissue Levels of Very Long Chain Fatty Acids (VLCFAs)

Tissue Effects Suggest Promising CNS Activity Following 25 Weeks of Exposure

http://www.prnewswire.com/news-releases/viking-therapeutics-announces-top-line-results-from-proof-of-concept-study-of-vk0214-in-in-vivo-model-of-x-linked-adrenoleukodystrophy-x-ald-300530670.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VKTX News